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Abstract
MAPT has been repeatedly linked with Parkinson’s disease (PD) in association studies. Although tau deposition may be seen in PD, its
relevance to the pathogenesis of the condition remains unclear. The presence of tau-positive inclusions is, however, the defining feature of
progressive supranuclear palsy (PSP), which may often be clinically misdiagnosed as idiopathic PD. On a genetic level, variants in MAPT
re the strongest risk factor for PSP. These facts raise the question whether the MAPT association in PD results from contamination with
nrecognized cases of PSP. Using only neuropathologically proven PD, we show that the MAPT association remains and is independent of
he PSP Association.
2012 Elsevier Inc.
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Open access under CC BY license.1. Introduction
To date, several large-scale genome-wide association
studies (GWAS) have been completed for Parkinson’s
disease (PD), culminating in a recently published meta-
analysis that identified 16 loci surpassing the threshold
for genome-wide significance (International Parkinson’s
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0203 448 4255 ext 84255, fax: 0207 278 5616.E-mail address: n.wood@ucl.ac.uk (N. Wood).
0197-4580 © 2012 Elsevier Inc.
doi:10.1016/j.neurobiolaging.2011.11.001
Open access under CC BY license.Disease Genomics Consortium et al., 2011; International
Parkinson’s Disease Genomics Consortium and Well-
come Trust, Case Control Consortium 2, 2011; Satake et
al., 2009; Simón-Sánchez et al., 2009; UK Parkinson’s
Disease Consortium et al., 2011). Of these 16 loci, some
are predictable findings, while others offer the new in-
sights into the pathogenesis of the disease. For example,
from a neuropathological perspective, the discovery that
variants in SNCA act as a risk factor for PD is consistent
with the deposition of aggregated -synuclein in the PD
brain. The detection of variation in MAPT as a risk factor
in PD was unexpected, as the relevance of tau aggrega-
tion in PD remains unclear.
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838.e8 G. Charlesworth et al. / Neurobiology of Aging 33 (2012) 838.e7–838.e11Predictably, a number of tauopathies are associated with
common or rare variants in MAPT, including corticobasal
degeneration, frontotemporal dementia with parkinsonism
linked to chromosome 17, and progressive supranuclear
palsy (PSP) (Vandrovcova et al., 2009). In fact, variation in
MAPT is the strongest genetic risk factor for PSP. The
association with this condition is driven by a series of
polymorphisms in near complete linkage disequilibrium,
which form an extended haplotype, termed H1, that covers
the entire gene (Baker et al., 1999). Inheritance of 2 copies
of the risk haplotype in this region confers an odds ratio for
developing PSP of approximately 4 (Baker et al., 1999).
There can be considerable clinical overlap between PD
and PSP, especially in the earlier stages of the diseases.
Even with increased awareness, the rate of misdiagnosis of
idiopathic PD has been estimated at between 10% and 25%
in autopsy studies, and 6%–26% in community studies
(Hughes et al., 1992; Newman et al., 2009). In one autopsy
study of 100 cases of clinically diagnosed PD, 24 cases were
found to be misdiagnosed and 6 of these were PSP (Hughes
et al., 1992). It is probable that large GWAS, using clini-
cally diagnosed PD cases, will contain some individuals
with PSP. Despite the potential for clinical confusion, PSP
is neuropathologically distinct from idiopathic PD. PSP is
classified as a primary tauopathy and is characterized mor-
phologically by deposition of 4-repeat tau in neurons as
neurofibrillary tangles and in both astrocytes and oligoden-
droglia as tufted astrocytes and coiled bodies, respectively.
The morphological characteristics and anatomical distribu-
tion of the tau pathology and the biochemical composition
of the tau lesions are different from those seen in Alzhei-
mer’s disease (Hauw et al., 1994). PD, on the other hand, is
classified as a synucleinopathy, characterized by abnormal
fibrillar cytoplasmic inclusions, termed Lewy bodies, of
which the principal protein component is -synuclein
Braak et al., 2003).
Given the strength of the association between MAPT
ith PSP, it has been suggested that the tau signal seen in
arkinson’s disease association studies might be the result
f unrecognized PSP contamination of the case cohort.
herefore, in order to answer this important question, we
erformed a focused analysis of our pathologically proven
D cases from our recent GWAS datasets (International
arkinson’s Disease Genomics Consortium et al., 2011).
. Methods
Cases were selected from two brain banks in London
ith a confirmed primary neuropathological diagnosis of
D and genotype data from the discovery or replication
hase of our recent meta-analysis. Neuropathological diag-
osis had been made by an experienced neuropathologist
nd was based on accepted morphological criteria (Ince et
l., 2008). Two hundred forty-five pathologically proven
D cases and 5445 controls from the discovery phase and40 cases and 4537 controls from the replication phase of
ur published meta-analysis were suitable for this analysis.
ome of the pathological samples were used in previous
tudies (De Silva et al., 2002; Vandrovcova et al., 2009).
The primary analysis focused on a region approximately
00 kilobase (kb) either side of MAPT. The single nucleo-
ide polymorphisms (SNPs) tested for association in this
egion were selected on the basis that they had achieved
enome-wide significance in the UK samples used in the
iscovery phase of our GWAS meta-analysis and had also
een genotyped on the custom-built immunochip used for
he replication phase. Eight SNPs met these requirements
rs393152, rs1635291, rs7215239, rs1237319, rs17690703,
s17769552, rs1981997, and rs8070723). None of the SNPs
n MAPT chosen by this method are in significant linkage
disequilibrium with the SNPs used by Vandrocova et al.
(2009) in their MAPT haplotype analysis (maximum r2  0.2).
In earlier GWAS, the region surrounding -synuclein
(SNCA) has consistently been shown to be the locus most
strongly associated with PD (International Parkinson’s Dis-
ease Genomics Consortium et al., 2011; UK Parkinson’s
Disease Consortium et al., 2011; Satake et al., 2009). Thus,
in order to verify that this analysis had sufficient power
to detect previously well-documented associations, we
also included the SNPs in a second 1 megabase (Mb)
region spanning SNCA that met the same requirements as
above. Two SNPs were available for testing (rs356220
and rs2736990).
The association analyses for the discovery and replica-
tion datasets were performed separately using PLINK (Pur-
cell et al., 2007). Subsequently, a meta-analysis of the 2
datasets was performed using the same software. Fixed and
random effects models were used to generate p-values and
the I2 index was used to quantify heterogeneity between the
tudies.
. Results
After review of the reports, 385 cases of neuropathologi-
ally proven idiopathic PD remained for analysis. Two
undred forty-five were male and 140 female. The primary
nalysis demonstrated statistically significant association in
he 8 SNPs spanning the MAPT gene (Table 1 and Fig. 1A).
The SNP showing strongest association in this study was
rs17690703, which had a p-value of 0.001225 and was
calculated to confer an odds ratio of 0.75 per minor allele
dose. Association at rs8070723 confirms previous data sug-
gesting that the additional risk in PD is conferred by the H1
haplotype of the MAPT inversion (Simón-Sánchez et al.,
2009). Further dissection of subhaplotypes was not possible
with the limited number of SNPs included in this study. In
particular, no proxy in sufficient linkage disequilibrium
(r2  0.8) with the H1-specific SNP rs242557, which has
previously been implicated in PSP but not PD, was available
for testing (Wider et al., 2010).
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838.e9G. Charlesworth et al. / Neurobiology of Aging 33 (2012) 838.e7–838.e11The results of the secondary analysis using SNPs span-
ning SNCA confirms this study’s ability to detect the pre-
dicted association with this region using only the relatively
small subpopulation of neuropathologically confirmed cases
of PD (Table 2 and Fig. 1B). Rs356220, the SNP showing
he strongest association in this study, had a p-value of
.001167 (fixed effects model) and was calculated to confer
n odds ratio of 1.31 per minor allele dose. The I2 index of
0.35 indicated some heterogeneity between the 2 data-
sets, but was well below the standard cutoff point of 0.75.
Furthermore, this SNP is in high linkage disequilibrium
Table 1
SNPs in a 1-Mb region spanning MAPT showing statistically significant a
llele frequency (MAF) and odds ratio per minor allele dose
SNP
reference
Physical
position
p Value
(fixed effects)
p
(ra
s17690703 41281077 0.001225 0.0
s17769552 41283070 0.001485 0.0
s7215239 41123556 0.002481 0.0
s12373139 41279910 0.002484 0.0
s8070723 41436901 0.002529 0.0
s393152 41074926 0.002701 0.0
s1635291 41107696 0.003155 0.0
s1981997 41412603 0.003257 0.0
ey: Mb, megabase; SNP, single nucleotide polymorphism.
Fig. 1. Graphical representation of the physical position of SNPs tested acr
(LD). A diamond represents the top hit, which is the reference for the LD c
against the right-hand axis.(r2  0.9) with and shows the same direction of effect as
the top SNP from the largest meta-analysis published to date
(rs356219; not included in this study as not common to both
genotyping platforms) suggesting a consistent pattern of
association (International Parkinson’s Disease Genomics
Consortium et al., 2011).
4. Discussion
Clinical misdiagnosis has the potential to introduce con-
tamination into association analysis. With regard to PD
ion with p values in fixed and random effects models, I2 index, minor
ffects)
I2 index MAF Odds ratio per
minor allele dose
0.00 0.28 0.75
0.00 0.24 0.74
0.00 0.26 0.76
0.00 0.24 0.76
0.00 0.24 0.76
0.00 0.24 0.76
0.00 0.26 0.77
0.00 0.24 0.76
MAPT (A) and SNCA (B) loci, with p-values and linkage disequilibrium
ions. Recombination rate in centiMorgan per megabase (cMMb) is plottedssociat
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838.e10 G. Charlesworth et al. / Neurobiology of Aging 33 (2012) 838.e7–838.e11GWAS, PSP contamination is of particular concern as the
association between PSP and the MAPT locus is particularly
strong. In this analysis, we relied solely on neuropatholog-
ical diagnosis as the inclusion criterion for the case cohort.
The results confirm that the region surrounding MAPT is
associated with idiopathic PD in our neuropathologically
proven PD cohort and, therefore, that this association does
not result from contamination with primary tauopathies,
such as PSP. Although the gene most likely to be respon-
sible for the association signal remains MAPT itself, this
gene is located in a block of near complete linkage disequi-
librium that extends over a total of nearly 2 Mb on chro-
mosome 17. It is conceivable, therefore, that a different
gene within this haplotype block may in fact be driving the
association.
Accepting MAPT as the most likely candidate, the per-
sistence of the association at this locus in pathologically
proven PD raises the possibility that that dysfunction of tau
may in fact be pathogenic in PD. Variants in MAPT may act
either to increase expression or alter the splicing of tau so as
to favor its aggregation. It is already known that the H1c
haplotype, which underlies the risk in PSP, results in in-
creased expression of tau, particularly of 4 repeat-contain-
ing transcripts (Myers et al., 2007). Recently, it has also
become increasingly clear that, in many neurodegenerative
diseases, the aggregation of one protein may often be asso-
ciated with or even induce the aggregation of others (Hi-
gashi et al., 2007). On a genetic level, studies in clinically
defined PD have suggested that genotypes at the MAPT and
SNCA loci act synergistically to confer susceptibility to PD
and that variation at MAPT may be particularly associated
with cognitive decline (Goris et al., 2007; Williams-Gray et
al., 2009). Certainly, Alzheimer-like tau pathology has long
been known to coexist with the morphological changes
typical of idiopathic PD. This has mostly been viewed as a
consequence of pathological aging or coexistent early Alz-
heimer’s disease, rather than as being an intrinsic part of the
pathogenic pathway of PD itself. Coexistent Alzheimer’s
disease seems, however, unlikely to be able to fully explain
the MAPT association in idiopathic PD as a recent large
GWAS in Alzheimer’s disease failed to demonstrate any
association at this locus (Naj et al., 2011). Significant tau pathol-
ogy has also been noted in some monogenic forms of PD, includ-
ing in some cases resulting from LRRK2 mutation and in some
Table 2
SNPs in a 1-Mb region spanning SNCA showing statistically significant a
llele frequency (MAF), and odds ratio per minor allele dose
SNP
reference
Physical
position
p Value
(fixed effects)
p V
(ra
s356220 90860363 0.001167 0.0
rs2736990 90897564 0.005539 0.0
Key: SNP, single nucleotide polymorphism.members of the Contursi kindred, who carry the A53T SNCAmutation, as well as in -synuclein overexpressing transgenic
ice (Devine and Lewis, 2008; Haggerty et al., 2011).
It is likely that more detailed neuropathological studies of
au pathology in the brains of individuals with idiopathic and
enetic forms of PD will be required to fully dissect out its role
n the pathogenesis of this condition. One promising approach
ay be to search for a correlation between the extent of tau
athology in idiopathic PD and the genotype at the MAPT
ocus. The existence of such a correlation would support the
dea of a direct effect of these variants on tau aggregation.
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